



Morgan Stanley ESG Conference 2020

Phil Thomson

President, Global Affairs, GSK

9 December 2020

Everyone at GSK is focused on our **three long-term** priorities, all powered by our **performance focused** culture.

Innovation

Performance

Trust

Culture



Trust aims to deliver long-term sustainable impact and reduce risk



Innovation

By using our
science and technology
to address health needs



New medical innovations

Develop differentiated, high-quality and needed medicines, vaccines and consumer healthcare products to improve health

Global health

Improve global health impact through R&D for infectious diseases that affect children and adolescents in developing countries focusing on HIV, malaria and TB

Health security

Help the world to better prepare for future disease outbreaks with pandemic potential, and tackle antimicrobial resistance

Performance

By making our products
affordable and available



Pricing

Improve the health of millions of people each year by making our products available at responsible prices that are sustainable for our business

Product reach

Use access strategies to reach 800 million underserved people in developing countries with our products by 2025

Healthcare access

Partner to improve disease prevention, awareness and access to healthcare services for 12 million people by 2025

Trust

By being a
modern employer



Engaged people

Achieve and maintain a competitive employee engagement score by 2022

Inclusion and diversity

Accelerate our progress on inclusion and diversity, aiming for over 37% female representation in senior roles and recognition in global LGBT+ indices, by 2022

Health, wellbeing and development

Be a leading company in how we support employee health, wellbeing and personal development

Being a responsible business

Reliable supply

Commit to quality, safety and reliable supply of our products for patients and consumers

Ethics and values

Operate an ethical, values-driven culture, in which any issues are responded to swiftly and transparently

Data and engagement


Use data responsibly and transparently. Improve patient and scientific engagement

Environment*

Net zero impact on climate and net positive impact on nature by 2030


* New environmental goals announced November 2020

Trust reflects priority ESG topics for GSK




* New environmental goals announced November 2020

Trust reflects priority ESG topics for GSK



Trust reflects priority ESG topics for GSK



We measure progress on Trust through target KPIs



Product reach

Aim to use access strategies to reach 800 million underserved people in developing countries with our products by 2025.

> **Performance:** Since we set the target in 2018 our products have reached over **192 million people**.

Healthcare access

Aim to partner to improve disease prevention, awareness and access to healthcare services for 12 million people by 2025.

> **Performance:** Since we set the target in **2018** we have reached nearly **8 million** people through these partnerships.

Engaged people

Aim to achieve and maintain a competitive employee engagement score by 2022.

> **Performance:** In 2020, Record response (85%) to our employee survey, with **engagement score of 84%**

Inclusion and diversity

Aim to have over 37% female representation in senior roles 2022.

> **Performance:** Women represent **36% of all senior management** roles (SVP/VP level)


Environment

Aim to reduce our environmental impact by one quarter by 2030

> **Performance:** Since we set our environmental targets in 2010 we have:

- Reduced carbon emissions by 34%,
- Reduced waste to landfill by 78%
- Reduced total water use by 31%

Trust: Key developments in 2020



COVID-19

- Focus on future pandemic preparedness
- Progress on solutions: 3 vaccine approaches in the clinic, 2 therapeutics in pivotal studies
- Committed to affordable pricing and global access

Global Health

- Progress in AMR R&D and launch of AMR Action Fund
- FDA approval of Tivicay PD and filed EU regulatory submission
- Positive final phase II results for candidate TB vaccine and collaboration with the Bill & Melinda Gates Medical Research Institute
- GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age

Environment

- New ambitious targets across our different businesses
- Net zero impact on climate by 2030 and net positive impact on nature by 2030

People

- New inclusion and diversity commitments

COVID-19 virus



Janneth, Investigator, Tres Cantos



Wind turbine at GSK Ware

ESG leader in key indices/benchmarks



Agency	Type of score	Current score	Sector ranking
 SUSTAINALYTICS	ESG score and ranking	22.1	Best in industry score among larger pharma market cap
 Dow Jones Sustainability Indices <small>Powered by the S&P Global CSA</small>	ESG score and ranking	87	2 nd in sector
 MSCI <small>ESG Research</small>	ESG score and ranking	AA	Top 10% of sector
 vigeo eiris	ESG score and ranking	62	1 st in the sector
 ISS-oekom	ESG score and ranking	B	1 st in sector
 FTSE4Good	ESG score and ranking	4.5	In the top 5 of our sector
 access to medicine index	Access score and ranking	4.01	1 st
 antimicrobial resistance benchmark	AMR score and ranking	86%	Lead the sector
 CDP	Carbon score Water score Supplier Engagement ranking	A for Water B for Carbon Supplier Engagement Leader	7 th in the sector